253 related articles for article (PubMed ID: 20010156)
21. Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy.
Kinjo K; Sato H; Sakata Y; Nakatani D; Mizuno H; Shimizu M; Nishino M; Ito H; Tanouchi J; Nanto S; Hori M;
Am J Cardiol; 2005 Sep; 96(5):617-21. PubMed ID: 16125481
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
[TBL] [Abstract][Full Text] [Related]
23. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
24. High-Sensitivity C-Reactive Protein and Statin Initiation.
Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
[TBL] [Abstract][Full Text] [Related]
25. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Field KM
Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
[TBL] [Abstract][Full Text] [Related]
26. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
Eur Heart J; 2007 Jun; 28(11):1374-81. PubMed ID: 17242007
[TBL] [Abstract][Full Text] [Related]
27. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
[TBL] [Abstract][Full Text] [Related]
29. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein levels and outcomes after statin therapy.
Cohen B; Singh D
N Engl J Med; 2005 Apr; 352(15):1603-5; author reply 1603-5. PubMed ID: 15829545
[No Abstract] [Full Text] [Related]
31. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
32. C-reactive protein: a novel marker of cardiovascular risk.
Shah SH; Newby LK
Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
[TBL] [Abstract][Full Text] [Related]
33. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
Samson RH; Nair DG
Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
[TBL] [Abstract][Full Text] [Related]
34. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome.
Mielniczuk LM; Pfeffer MA; Lewis EF; Blazing MA; de Lemos JA; Shui A; Mohanavelu S; Califf RM; Braunwald E
Am Heart J; 2008 Apr; 155(4):725-31. PubMed ID: 18371483
[TBL] [Abstract][Full Text] [Related]
35. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
[TBL] [Abstract][Full Text] [Related]
36. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Scheen AJ
Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
[TBL] [Abstract][Full Text] [Related]
37. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
Windgassen EB; Funtowicz L; Lunsford TN; Harris LA; Mulvagh SL
Postgrad Med; 2011 Jan; 123(1):114-9. PubMed ID: 21293091
[TBL] [Abstract][Full Text] [Related]
38. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
39. Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
Shishehbor MH; Patel T; Bhatt DL
Cleve Clin J Med; 2006 Aug; 73(8):760-6. PubMed ID: 16913201
[TBL] [Abstract][Full Text] [Related]
40. [CRP level as risk marker of cardiovascular disease?].
Thelle DS; Arnesen E
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):512-4. PubMed ID: 20224622
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
